Ling-shao Zao-ren Granule for improving female Overactive Bladder symptom: a randomized, double-blind, placebo-controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021407

Enrollment

Unknown

Registered

2019-02-19

Start date

2017-01-31

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder symptom

Interventions

Group A:g Tolterodine Tartrate Sustained Release Tablets combination Ling Shao Zaoren Granule

Group B:Tolterodine Tartrate Sustained Release Tablets combination placebo,

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. in line with diagnostic criteria for Chinese and Western medicine; 2. between 18 and 60 years of age between women; 3. nearly a week has not been used to treat OAB Chinese and Western medicine; 4. signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. urinary tract infection and lower urinary tract obstruction patients; 2. neurogenic bladder; 3. patients with urethral dysfunction; 4. urinary retention in patients; 5. patients with myasthenia gravis; 6. patients with ulcerative colitis; 7. narrow angle glaucoma history; 8. the researchers can not meet with the completion of the study of patients; 9. patients with tartrate tartrate tablets allergy sufferers 10. residual urine volume> 50ml of patients; 11. does not meet the inclusion criteria, not according to the provisions of medication, can not determine the efficacy, or incomplete information such as the impact of judgment.

Design outcomes

Primary

Measure	Time frame
overactive bladder symptom scale (OABSS) score;	—

Countries

China

Contacts

Public ContactJianwu Shen

Xiyuan Hospital, CACMS

497390415@qq.com+86 13581972102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026